My watch list
my.chemeurope.com  
Login  

Dual Drug Backboned Shattering Polymeric Theranostic Nanomedicine for Synergistic Eradication of Patient‐Derived Lung Cancer

Abstract

Most of the current nanoparticle‐based therapeutics worldwide failing in clinical trials face three major challenges: (i) lack of an optimum drug delivery platform with precise composition, (ii) lack of a method of directly monitoring the fate of a specific drug rather than using any other labelling molecules as a compromise, and (iii) lack of reliable cancer models with high fidelity for drug screen and evaluation. Here, starting from a PP2A inhibitor demethylcantharidin (DMC) and cisplatin, the design of a dual sensitive dual drug backboned shattering polymer (DDBSP) with exact composition at a fixed DMC/Pt ratio for precise nanomedicine is shown. DDBSP self‐assembled nanoparticle (DD‐NP) can be triggered intracellularly to break down in a chain‐shattering manner to release the dual drugs payload. Moreover, DD‐NP with extremely high Pt heavy metal content in the polymer chain can directly track the drug itself via Pt‐based drug‐mediated computer tomography and ICP‐MS both in vitro and in vivo. Finally, DD‐NP is used to eradicate the tumor burden on a high‐fidelity patient‐derived lung cancer model for the first time.

Dual drug backboned shattering polymeric theranostic nanomedicine that can be triggered intracellularly to breakdown in a chain‐shattering manner to release the dual drugs payload is developed. It can directly track the drug itself via Pt‐based drug‐mediated computer tomography and eradicate the tumor burden on a high‐fidelity patient‐derived lung cancer model.

Authors:   Yuwei Cong, Haihua Xiao, Hejian Xiong, Zigui Wang, Jianxun Ding, Chan Li, Xuesi Chen, Xing‐Jie Liang, Dongfang Zhou, Yubin Huang
Journal:   Advanced Materials
Year:   2018
Pages:   n/a
DOI:   10.1002/adma.201706220
Publication date:   19-Jan-2018
Facts, background information, dossiers
  • nanomedicine
  • lung cancer
  • molecules
  • drugs
  • drug delivery
  • clinical trials
  • cisplatin
  • cancer
More about Wiley
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE